Azodopa is the first photoswitchable dopamine agonist with demonstrated efficacy in wild-type animals

we present the analysis of a series of GPCRs whose activity has been shown to affect the lifespan of animal

Orthosteric dose increases drive continuously stronger responses; NAMs and PAMs have structural ceilings For complex GPCR systems, this boundary is a strategic advantage: NAMs can only shift an agonist curve NAMs, PAMs, and Subtle Mechanistic Traps Modulators are frequently labeled correctly but characterized Kenakin  stressed that low-alpha NAMs can resemble competitive antagonists unless deeper kinetic or concentration-range

Nyla Naim, Dr. Michael Lemieux & Dr. Jason Nasse About Dr. Nyla Naim Nyla is a Senior Scientist on the Scientific Support Team at Addgene . Nyla supports biomedical research by connecting researchers with resources and promoting reproducible Nyla Naim on the web LinkedIn Dr. GPCR Ecosystem About Dr.

Nicolas Gilles is an expert in the study of animal toxins. He is pioneering the investigation of animal toxins acting on GPCRs, the largest therapeutic target class

moment of her scientific life was designing a compound in a HEK cell from a hypothesis, putting it in an animal moment was designing a compound in HEK293 cells from a hypothesis at Novo Nordisk, putting it in an animal 25:26 — The HEK293 experiment that predicted the animal 31:21 — Tools for the next decade: biosensors